Market Overview

UPDATE: J.P. Morgan Reiterates Neutral Rating, Raises PT on HCP on Model Update

Share:
Related HCP
Benzinga's Top Initiations
7 Largest Price Target Changes For Friday
Finding Some Of The Best-Quality Dividend Growth Stocks Using The Piotroski F Score (Seeking Alpha)

In a report published Friday, J.P. Morgan reiterated its Neutral rating on HCP (NYSE: HCP), and raised its price target from $48.00 to $50.00.

J.P. Morgan noted, “We retain our Neutral rating on HCP due to a number of factors. On the valuation front, the stock trades at slight premiums to the health care REIT averages (particularly on an AFFO basis), which we do believe is justified considering its improved growth profile following recent investment activity and lease restructuring. However, we continue to maintain our bias toward more economically leveraged property types at this point in the cycle.”

HCP closed on Thursday at $48.88.

Latest Ratings for HCP

DateFirmActionFromTo
Jul 2016Raymond JamesInitiates Coverage onUnderperform
Jul 2016Goldman SachsUpgradesNeutral
Jun 2016Morgan StanleyDowngradesEqual-weightUnderweight

View More Analyst Ratings for HCP
View the Latest Analyst Ratings

Posted-In: J.P. MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (HCP)

View Comments and Join the Discussion!